Roche Senior Developer Salaries in Hagerstown, MD
The average Roche Senior Developer in Hagerstown, MD earns an estimated $156,549 annually, which includes an estimated base salary of $133,077 with a $23,473 bonus. Roche's Senior Developer compensation is $18,850 more than the US average for a Senior Developer. Senior Developer salaries at Roche in Hagerstown, MD can range from $52,000 - $500,000 with equity ranging from 0-25k.
In Hagerstown, MD, The Engineering Department at Roche earns $9,989 more on average than the Design Department. Comparably data has a total of 2 salary records from Roche Senior Developers.
Last updated 4 months ago.
- $133,077
- avg. base
- $23,473
- avg. bonus
- 0-25k
- equity range
Senior Developer Salaries at Roche
In Hagerstown, MD, Senior Developers earn $4,897 more than Senior Developers, and $5,973 less than Principal Engineers.
Compensation at Roche by Department
In Hagerstown, MD, The Engineering Department averages $9,989 more than the Design Department, and $3,891 less than the Business Development Department
Average Equity for Senior Developer at Roche
In Hagerstown, MD, the average Senior Developer at Roche receives $25k of stock in equity.
Recent Senior Developer Salaries at Roche
Senior Developer Compensation by Gender (All Companies)
The average female Senior Developer at companies similar size to Roche reported making $146,554, while the average male Senior Developer at similar sized companies reported making $156,727.
Senior Developer Compensation by Ethnicity (All Companies)
The average Asian or Pacific Islander Senior Developer at companies similar size to Roche reported making $153,064, while the average Native American Senior Developer at similar sized companies reported making $101,264.
How Senior Developers at Roche Rate Their Compensation
The majority of Senior Developers at Roche believe they're compensated fairly. 100% of Senior Developers at Roche say they receive annual bonuses, and the vast majority (79%) are satisfied with their benefits. See more compensation ratings at Roche
